[HTA Rapid report-Lorviqua (ALK+ NSCLC)]
Center for Drug Evaluation
Record ID 32018013840
Chinese (Mandarin)
Authors' results and conclusions:
Evaluates Lorviqua (Lorlatinib) for ALK+ NSCLC, expanding its indication to second-line treatment after Brigatinib. Clinical data from Study 1001 and Lu et al. 2022 trials show median PFS: 2.8–6.9 months. Financial impact: NT$1.5 billion in year one, decreasing over five years.
Details
Project Status:
Completed
Year Published:
2024
URL for published report:
https://www.cde.org.tw/media/0y0plqip/11302_11_%E8%A8%8E%E8%AB%96%E6%A1%88%E7%AC%AC9%E6%A1%88_lorviqua.pdf?mediaDL=true
English language abstract:
There is no English language summary available
Publication Type:
Rapid Review
MeSH Terms
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Anaplastic Lymphoma Kinase
- Lactams
- Pyrazoles
- Aminopyridines
Contact
Organisation Name:
Center for Drug Evaluation
Contact Address:
3F.,No.465, Sec.6, Zhongxiao E. Rd., Taipei 11557, Taiwan. R.O.C.
Contact Name:
Li Ying (Grace) Huang
Contact Email:
lyhuang277@cde.org.tw
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.